5 October 2023
Cambridge Cognition Holdings Plc
("Cambridge Cognition", the "Group" or the "Company")
Issue of Warrants
Cambridge Cognition Holdings plc (AIM: COG), which develops and markets digital solutions to assess brain health, announces, further to the Company's announcement on 26 September 2023, that the Company has issued Claret European Specialty Lending Company III, S.à r.l. ("Claret") with warrants to subscribe for 722,565 new ordinary shares of 1 pence each in the capital of the Company ("Ordinary Shares") at an exercise price of 74.734p.
Enquiries
| Cambridge Cognition Holdings Plc? Matthew Stork, Chief Executive Officer? Stephen Symonds, Chief Financial Officer?
| Tel: 012 2381 0700? |
| Panmure Gordon (UK) Limited (NOMAD and Joint Broker)? Freddy Crossley / Emma Earl / Mark Rodgers Rupert Dearden?
| Tel: 020 7886 2500? (Corporate Finance)? (Corporate Broking)? |
| Dowgate Capital Limited (Joint Broker)? David Poutney / James Serjeant?
| Tel: 020 3903 7715? ? |
| IFC Advisory Ltd (Financial PR and IR)? Tim Metcalfe / Graham Herring / Zach Cohen? | Tel: 020 3934 6630? ?cog@investor-focus.co.uk |
About Cambridge Cognition
Cambridge Cognition is a technology company developing digital health products to better understand, detect and treat conditions affecting brain health. The Company's software products assess cognitive health in patients worldwide to improve clinical trial outcomes, identify and stratify patients early and improve global efficiency in pharmaceutical and healthcare industries.
For further information visit www.cambridgecognition.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.